Injectable Supramolecular Hydrogels for In Situ Programming of CAR-T Cells towards Solid Tumor Immunotherapy

An injectable supramolecular hydrogel system has been designed to load plasmid CAR with T cell specific CD2 promoter, which successfully achieved in situ fabrication and effective accumulation of CAR-T cells at the tumor site in humanized mice models.